Pharmacotherapy approaches to antifungal prophylaxis

Bibliography

• Cornely OA, Aversa F, Cook P, Evaluating the role of prophylaxis in the management of invasive fungal infections in patients with hematologic malignancy. Eur J Haematol 2011;87:289-301
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Castanheira M, Lockhart SR, Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata. J Clin Microbiol 2012;50:1199-203
   PubMed Web of Science ®Google Scholar
• Wilkerson J, McPherson C, Donze A. Fluconazole to prevent systemic fungal infections in infants: reviewing the evidence. Neonatal Netw 2010;29:323-33
   PubMedGoogle Scholar
• McGuire W, Clerihew L. The effect of fluconazole prophylaxis in very low birthweight infants is overestimated by before-after studies. Arch Dis Child Fetal Neonatal Ed 2010;95:F182-7
   Web of Science ®Google Scholar
• Bhat V, Fojas M, Saslow JG, Twice-weekly fluconazole prophylaxis in premature infants: association with cholestasis. Pediatr Int 2011;53:475-9
   PubMedGoogle Scholar
• Aziz M, Patel AL, Losavio J, Efficacy of fluconazole prophylaxis for prevention of invasive fungal infection in extremely low birth weight infants. Pediatr Infect Dis J 2010;29:352-6
   PubMed Web of Science ®Google Scholar
• Kaufman DA, Cuff AL, Wamstad JB, Fluconazole prophylaxis in extremely low birth weight infants and neurodevelopmental outcomes and quality of life at 8 to 10 years of age. J Pediatr 2011;158:759-65
   PubMedGoogle Scholar
• Reed BN, Caudle KE, Rogers PD. Fluconazole prophylaxis in high-risk neonates. Ann Pharmacother 2010;44:178-84
   PubMedGoogle Scholar
• Manzoni P, Mostert M, Stronati M. Lactoferrin for prevention of neonatal infections. Curr Opin Infect Dis 2011;24:177-82
   PubMed Web of Science ®Google Scholar
• Bao Y, Du LZ, Shi LP, Clinical significance of oral fluconazole prophylaxis against invasive fungal infection in preterm neonates with peripherally inserted central catheters. Zhonghua Er Ke Za Zhi 2010;48:510-13
   PubMedGoogle Scholar
• Gardner AH, Prodhan P, Stovall SH, Fungal infections and antifungal prophylaxis in pediatric cardiac extracorporeal life support. J Thorac Cardiovasc Surg 2012;143:689-95
   PubMedGoogle Scholar
• Giacchino M, Milano GM, Carraro F, Current evidence of antifungal prophylaxis and therapy in pediatric patients. Pediatr Rep 2011;3:e6
   Google Scholar
• Dvorak CC, Fisher BT, Sung L, Antifungal prophylaxis in pediatric hematology/oncology: new choices & new data. Pediatr Blood Cancer 2011; Epub ahead of print
   Google Scholar
• Lehrnbecher T, Groll AH. Micafungin: a brief review of pharmacology, safety, and antifungal efficacy in pediatric patients. Pediatr Blood Cancer 2010;55:229-32
   PubMed Web of Science ®Google Scholar
• Bochennek K, Tramsen L, Schedler N, Liposomal amphotericin B twice weekly as antifungal prophylaxis in paediatric haematological malignancy patients. Clin Microbiol Infect 2011;17:1868-74
   PubMed Web of Science ®Google Scholar
• Kim YJ, Sung KW, Hwang HS, Efficacy of itraconazole prophylaxis for autologous stem cell transplantation in children with high-risk solid tumors: a prospective double-blind randomized study. Yonsei Med J 2011;52:293-300
   PubMedGoogle Scholar
• Cronin S, Chandrasekar PH. Safety of triazole antifungal drugs in patients with cancer. J Antimicrob Chemother 2010;65:410-16
   PubMed Web of Science ®Google Scholar
• Ziakas PD, Kourbeti IS, Voulgarelis M, Effectiveness of systemic antifungal prophylaxis in patients with neutropenia after chemotherapy: a meta-analysis of randomized controlled trials. Clin Ther 2010;32:2316-36
   PubMedGoogle Scholar
• Pechlivanoglou P, De Vries R, Daenen SM, Cost benefit and cost effectiveness of antifungal prophylaxis in immunocompromised patients treated for haematological malignancies: reviewing the available evidence. Pharmacoeconomics 2011;29:737-51
   PubMedGoogle Scholar
• Rogers TR, Slavin MA, Donnelly JP. Antifungal prophylaxis during treatment for haematological malignancies: are we there yet? Br J Haematol 2011;153:681-97
   PubMedGoogle Scholar
• Girmenia C, Frustaci AM, Gentile G, Posaconazole prophylaxis during front-line chemotherapy of acute myeloid leukemia: a single-center, real-life experience. Haematologica 2012;97:560-7
   PubMed Web of Science ®Google Scholar
• Vehreschild JJ, Ruping MJ, Wisplinghoff H, Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort. J Antimicrob Chemother 2010;65:1466-71
   PubMed Web of Science ®Google Scholar
• Chabrol A, Cuzin L, Huguet F, Prophylaxis of invasive aspergillosis with voriconazole or caspofungin during building work in patients with acute leukemia. Haematologica 2010;95:996-1003
   PubMed Web of Science ®Google Scholar
• Cattaneo C, Monte S, Algarotti A, Itraconazole vs fluconazole as a primary prophylaxis for fungal infections in HIV-infected patients in Thailand. Curr HIV Res 2011;9:334-8
   PubMedGoogle Scholar
• Wang J, Zhan P, Zhou R, Prophylaxis with itraconazole is more effective than prophylaxis with fluconazole in neutropenic patients with hematological malignancies: a meta-analysis of randomized-controlled trials. Med Oncol 2010;27:1082-8
   PubMed Web of Science ®Google Scholar
• Lazzaro C. Economic evaluation of posaconazole in prophylaxis of invasive fungal infections in Italian neutropenic patients with acute myeloid leukaemia or myelodysplastic syndrome. Infez Med 2010;18:91-103
   PubMedGoogle Scholar
• Imataki O, Kubota Y, Ohnishi H, Medical cost analysis for antifungal prophylaxis in neutropenic patients with hematological malignancies: a systematic simulation analysis. Support Care Cancer 2011;19:1657-65
   PubMed Web of Science ®Google Scholar
• Illmer T, Babatz J, Pursche S, Posaconazole prophylaxis during induction therapy of patients with acute lymphoblastic leukaemia. Mycoses 2011;54:e143-7
   Web of Science ®Google Scholar
• Al-Badriyeh D, Slavin M, Liew D, Pharmacoeconomic evaluation of voriconazole versus posaconazole for antifungal prophylaxis in acute myeloid leukaemia. J Antimicrob Chemother 2010;65:1052-61
   PubMed Web of Science ®Google Scholar
• Michallet M, Gangneux JP, Lafuma A, Cost effectiveness of posaconazole in the prophylaxis of invasive fungal infections in acute leukaemia patients for the French healthcare system. J Med Econ 2011;14:28-35
   PubMedGoogle Scholar
• Marks DI, Pagliuca A, Kibbler CC, Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation. Br J Haematol 2011;155:318-27
   PubMed Web of Science ®Google Scholar
• Salavert M, Jarque I. Is micafungin useful in the prophylaxis of invasive fungal disease in hematological patients? Enferm Infecc Microbiol Clin 2011;29(Suppl 2):43-9
   PubMedGoogle Scholar
• Nihtinen A, Anttila VJ, Ruutu T, Low incidence of invasive aspergillosis in allogeneic stem cell transplant recipients receiving amphotericin B inhalation prophylaxis. Transpl Infect Dis 2012;14:24-32
   PubMedGoogle Scholar
• Morello E, Pagani L, Coser P, Addition of aerosolized deoxycholate amphotericin B to systemic prophylaxis to prevent airways invasive fungal infections in allogeneic hematopoietic SCT: a single-center retrospective study. Bone Marrow Transplant 2011;46:132-6
   PubMedGoogle Scholar
• Xu LP, Tang FF, Liu DH, Secondary prophylaxis of invasive fungal infection in haematopoietic stem cell recipients. Zhonghua Nei Ke Za Zhi 2009;48:853-6
   PubMedGoogle Scholar
• Jansen JP, O'Sullivan AK, Lugtenburg E, Economic evaluation of posaconazole versus fluconazole prophylaxis in patients with graft-versus-host disease (GVHD) in the Netherlands. Ann Hematol 2010;89:919-26
   PubMed Web of Science ®Google Scholar
• De La Camara R, Jarque I, Sanz MA, Economic evaluation of posaconazole vs fluconazole in the prevention of invasive fungal infections in patients with GVHD following haematopoietic SCT. Bone Marrow Transplant 2010;45:925-32
   PubMedGoogle Scholar
• Martin T, Sharma M, Damon L, Voriconazole is safe and effective as prophylaxis for early and late fungal infections following allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 2010;12:45-50
   PubMedGoogle Scholar
• Mousset S, Bug G, Heinz WJ, Breakthrough zygomycosis on posaconazole prophylaxis after allogeneic stem cell transplantation. Transpl Infect Dis 2010;12:261-4
   PubMedGoogle Scholar
• Cordonnier C, Rovira M, Maertens J, Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study. Haematologica 2010;95:1762-8
   PubMed Web of Science ®Google Scholar
• Lyseng-Williamson KA. Posaconazole: a pharmacoeconomic review of its use in the prophylaxis of invasive fungal disease in immunocompromised hosts. Pharmacoeconomics 2011;29:251-68
   PubMed Web of Science ®Google Scholar
• Sanchez-Ortega I, Patino B, Arnan M, Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole vs itraconazole in allogeneic blood and marrow transplantation. Bone Marrow Transplant 2011;46:733-9
   PubMed Web of Science ®Google Scholar
• Keckich DW, Blair JE, Vikram HR, Reactivation of coccidioidomycosis despite antifungal prophylaxis in solid organ transplant recipients. Transplantation 2011;92:88-93
   PubMed Web of Science ®Google Scholar
• Paniagua Martin MJ, Marzoa Rivas R, Barge Caballero E, Efficacy and tolerance of different types of prophylaxis for prevention of early aspergillosis after heart transplantation. Transplant Proc 2010;42:3014-16
   PubMed Web of Science ®Google Scholar
• Avery RK. Antifungal prophylaxis in lung transplantation. Semin Respir Crit Care Med 2011;32:717-26
   PubMedGoogle Scholar
• Pinney MF, Rosenberg AF, Hampp C, Invasive fungal infections in lung transplant recipients not receiving routine systemic antifungal prophylaxis: 12-year experience at a university lung transplant center. Pharmacotherapy 2011;31:537-45
   PubMedGoogle Scholar
• Neoh CF, Snell GI, Kotsimbos T, Antifungal prophylaxis in lung transplantation-a world-wide survey. Am J Transplant 2011;11:361-6
   PubMedGoogle Scholar
• San-Juan R, Aguado JM, Lumbreras C, Universal prophylaxis with fluconazole for the prevention of early invasive fungal infection in low-risk liver transplant recipients. Transplantation 2011;92:346-50
   PubMedGoogle Scholar
• Pozo Laderas JC. Antifungal prophylaxis in HIV-seropositive liver transplant recipients. Rev Iberoam Micol 2011;28:183-90
   PubMedGoogle Scholar
• Chaiwarith R, Fakthongyoo A, Praparattanapan J, Itraconazole vs fluconazole as a primary prophylaxis for fungal infections in HIV-infected patients in Thailand. Curr HIV Res 2011;9:334-8
   PubMedGoogle Scholar
• Micol R, Tajahmady A, Lortholary O, Cost-effectiveness of primary prophylaxis of AIDS associated cryptococcosis in Cambodia. PLoS One 2010;5:e13856
   PubMed Web of Science ®Google Scholar
• Ray A, Ray S, George AT, Interventions for prevention and treatment of vulvovaginal candidiasis in women with HIV infection. Cochrane Database Syst Rev 2011;8:CD008739
   Google Scholar
• Iriyama N, Matsukawa Y, Miura K, Efficacy and safety of antifungal prophylaxis with oral itraconazole solution among patients receiving corticosteroids: who should be given prophylaxis? J Infect Chemother 2011;17:744-9
   PubMed Web of Science ®Google Scholar
• Freeman AF, Holland SM. Antimicrobial prophylaxis for primary immunodeficiencies. Curr Opin Allergy Clin Immunol 2009;9:525-30
   PubMed Web of Science ®Google Scholar
• Echeverria PM, Kett DH, Azoulay E. Candida prophylaxis and therapy in the ICU. Semin Respir Crit Care Med 2011;32:159-73
   PubMedGoogle Scholar
• Campoli P, Al Abdallah Q, Robitaille R, Concentration of antifungal agents within host cell membranes: a new paradigm governing the efficacy of prophylaxis. Antimicrob Agents Chemother 2011;55:5732-9
   PubMed Web of Science ®Google Scholar
• Glockner A. Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin: review of the literature. Eur J Med Res 2011;16:167-79
   PubMedGoogle Scholar
• Wilke M. Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin and its impact on use and costs: review of the literature. Eur J Med Res 2011;16:180-6
   PubMed Web of Science ®Google Scholar
• Cabezas J, Albaina O, Montanez D, Potential of anti-Candida antibodies in immunoprophylaxis. Immunotherapy 2010;2:171-83
   PubMed Web of Science ®Google Scholar
• Ianas V, Matthias KR, Klotz SA. Role of posaconazole in the treatment of oropharyngeal candidiasis. Infect Drug Resist 2010;3:45-51
   PubMedGoogle Scholar
• Wiederhold NP, Najvar LK, Bocanegra R, Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani. Antimicrob Agents Chemother 2010;54:1055-9
   PubMedGoogle Scholar
• Cataldo MA, Petrosillo N. Economic considerations of antifungal prophylaxis in patients undergoing surgical procedures. Ther Clin Risk Manag 2011;7:13-20
   PubMed Web of Science ®Google Scholar
• Kao LS, Fleming GM, Escamilla RJ, Antimicrobial prophylaxis and infection surveillance in extracorporeal membrane oxygenation patients: a multi-institutional survey of practice patterns. ASAIO J 2011;57:231-8
   PubMedGoogle Scholar
• Bohme A, Ruhnke M, Buchheidt D, Treatment of fungal infections in hematology and oncology–guidelines of the infectious diseases working party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2003;82(Suppl 2):S133-40
   Google Scholar
• Traunmuller F, Popovic M, Konz KH, Efficacy and safety of current drug therapies for invasive aspergillosis. Pharmacology 2011;88:213-24
   PubMedGoogle Scholar
• Beck-Sague CM, Jarvis WR. National nosocomial infections surveillance system. Secular trends in the epidemiology of nosocomial fungal infections in the United states 1980 – 1990. J Infect Dis 1993;167:1247-51
   PubMed Web of Science ®Google Scholar
• Kim J, Sudbery P. Candida albicans, a major human fungal pathogen. J Microbiol 2011;49:171-7
   PubMed Web of Science ®Google Scholar
• Mandal SM, Migliolo L, Franco OL, Identification of an antifungal peptide from Trapa natans fruits with inhibitory effects on Candida tropicalis biofilm formation. Peptides 2011;32:1741-7
   PubMed Web of Science ®Google Scholar
• Chandra J, Mukherjee PK, Leidich SD, Antifungal resistance of candidal biofilms formed on denture acrylic in vitro. J Dent Res 2001;80:903-8
   PubMed Web of Science ®Google Scholar
• Wong JH, Ng TB, Legowska A, Antifungal action of human cathelicidin fragment (LL13-37) on Candida albicans. Peptides 2011;32:1996-2002
   PubMed Web of Science ®Google Scholar
• Benincasa M, Scocchi M, Pacor S, Fungicidal activity of five cathelicidin peptides against clinically isolated yeasts. J Antimicrob Chemother 2006;58:950-9
   PubMed Web of Science ®Google Scholar
• Bolscher J, Nazmi K, van Marle J, Chimerization of lactoferricin and lactoferrampin peptides strongly potentiates the killing activity against Candida albicans. Biochem Cell Biol 2012; Epub ahead of print
   Google Scholar
• Kobayashi T, Kakeya H, Miyazaki T, Synergistic antifungal effect of lactoferrin with azole antifungals against Candida albicans and a proposal for a new treatment method for invasive candidiasis. Jpn J Infect Dis 2011;64:292-6
   PubMed Web of Science ®Google Scholar